Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for a Spectral Break or Curvature in the Spectrum of Astrophysical Neutrinos from 5 TeV to 10 PeV.

Physical review letters·2026
Same author

Clinical utility of ultra-widefield indocyanine green angiography in posterior uveitis.

Journal francais d'ophtalmologie·2025
Same author

Cytological vitreous findings in a patient with infantile neurological cutaneous and articular (CINCA) syndrome.

BMJ case reports·2025
Same author

Search for Extremely-High-Energy Neutrinos and First Constraints on the Ultrahigh-Energy Cosmic-Ray Proton Fraction with IceCube.

Physical review letters·2025
Same author

Measurement of Atmospheric Neutrino Oscillation Parameters Using Convolutional Neural Networks with 9.3 Years of Data in IceCube DeepCore.

Physical review letters·2025
Same author

Paracentral acute middle maculopathy (PAMM) in a patient treated with interferon-beta for multiple sclerosis.

Journal francais d'ophtalmologie·2025

Related Experiment Video

Updated: May 3, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Interleukin-6 blockade in ocular inflammatory diseases.

M Mesquida1, A Leszczynska, V Llorenç

  • 1Institut Clinic d'Oftalmologia, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

Clinical and Experimental Immunology
|February 18, 2014
PubMed
Summary

Interleukin-6 (IL-6) drives autoimmune inflammation, particularly in uveitis. Blocking IL-6 with tocilizumab shows promise for treating chronic ocular inflammatory diseases.

Keywords:
autoimmune diseasesinterleukin-6monoclonal antibodiestocilizumabuveitis

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.2K
Characterization of a Novel Human Organotypic Retinal Culture Technique
05:51

Characterization of a Novel Human Organotypic Retinal Culture Technique

Published on: June 9, 2021

3.9K

Related Experiment Videos

Last Updated: May 3, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.2K
Characterization of a Novel Human Organotypic Retinal Culture Technique
05:51

Characterization of a Novel Human Organotypic Retinal Culture Technique

Published on: June 9, 2021

3.9K

Area of Science:

  • Immunology
  • Ophthalmology
  • Rheumatology

Background:

  • Interleukin-6 (IL-6) is a pleiotropic cytokine crucial for host defense but implicated in autoimmune and chronic inflammatory diseases.
  • Elevated IL-6 levels are observed in ocular fluids of patients with refractory uveitis.
  • IL-6 plays a critical role in experimental autoimmune uveitis pathogenesis.

Purpose of the Study:

  • To discuss the fundamental biology of IL-6 and its role in autoimmune conditions.
  • To focus on the specific involvement of IL-6 in non-infectious uveitis.
  • To review the efficacy and safety of tocilizumab for treating ocular inflammatory diseases.

Main Methods:

  • Review of existing literature on IL-6 biology and its role in autoimmune diseases.
  • Analysis of experimental autoimmune uveitis models.
  • Examination of clinical data regarding tocilizumab therapy in uveitis patients.

Main Results:

  • IL-6 is essential for inducing inflammation in experimental autoimmune uveitis.
  • IL-6 blockade can suppress T helper type 17 (Th17) responses and ameliorate chronic inflammation.
  • Tocilizumab, an anti-IL-6 receptor antibody, has demonstrated effectiveness in treating uveitis.

Conclusions:

  • IL-6 is a significant contributor to the pathogenesis of non-infectious uveitis.
  • Targeting the IL-6 pathway with agents like tocilizumab offers a therapeutic strategy for ocular inflammation.
  • Tocilizumab presents a viable treatment option with a favorable efficacy and safety profile for ocular inflammatory conditions.